Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Emergent Biosolutions Inc

Healthcare US EBS

8.07USD
-0.37(4.38%)

Last update at 2026-06-05T20:00:00Z

Day Range

7.958.51
LowHigh

52 Week Range

4.7114.06
LowHigh

Fundamentals

  • Previous Close 8.44
  • Market Cap414.17M
  • Volume577738
  • P/E Ratio8.60
  • Dividend Yield-%
  • EBITDA208.90M
  • Revenue TTM742.90M
  • Revenue Per Share TTM13.89
  • Gross Profit TTM 367.30M
  • Diluted EPS TTM0.93

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 82.80M -142.90000M -731.20000M -221.70000M 314.40M
Minority interest - - - - -
Net income 52.60M -190.60000M -760.50000M -223.80000M 230.90M
Selling general administrative 186.10M 308.00M 372.90M 340.30M 347.50M
Selling and marketing expenses - - - - -
Gross profit 350.60M 375.40M 360.00M 427.20M 1035.20M
Reconciled depreciation 95.80M 108.80M 131.20M 143.30M 123.80M
Ebit 110.20M -52.20000M -168.10000M -166.00000M 352.60M
Ebitda 208.50M 53.40M -47.00000M -34.40000M 514.40M
Depreciation and amortization 98.30M 105.60M 121.10M 131.60M 161.80M
Non operating income net other - - - -11.70000M -3.70000M
Operating income 110.20M -108.70000M -726.40000M -166.00000M 352.60M
Other operating expenses 632.70M 1152.30M 1775.70M 1286.90M 1398.40M
Interest expense 59.30M 71.00M 87.90M 37.30M 34.50M
Tax provision 30.20M 47.70M 49.40M 2.10M 83.50M
Interest income 59.30M 71.00M 87.90M 37.30M 34.50M
Net interest income -59.30000M -71.00000M -79.00000M -37.30000M -34.50000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 30.20M 47.70M 29.30M 2.10M 83.50M
Total revenue 742.90M 1043.60M 1049.30M 1120.90M 1792.70M
Total operating expenses 240.40M 484.10M 1086.40M 593.20M 640.90M
Cost of revenue 392.30M 668.20M 689.30M 693.70M 757.50M
Total other income expense net -27.40000M -34.20000M -4.80000M -55.70000M -38.20000M
Discontinued operations - - - - -
Net income from continuing ops 52.60M -190.60000M -790.20000M -223.80000M 230.90M
Net income applicable to common shares 52.60M -190.60000M -760.50000M -223.80000M 230.90M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1318.60M 1389.70M 3166.60M 3166.60M 2959.00M
Intangible assets 436.50M 501.50M 728.80M 728.80M 604.60M
Earning assets - - - - -
Other current assets 29.50M 33.00M 57.90M 57.90M 70.50M
Total liab 796.00M 906.90M 1783.60M 1783.60M 1340.00M
Total stockholder equity 522.60M 482.80M 1383.00M 1383.00M 1619.00M
Deferred long term liab - - - 71.80M 94.90M
Other current liab 76.60M 98.80M 142.70M 169.10M 72.90M
Common stock 0.10M 0.10M 0.10M 0.10M 0.10M
Capital stock 0.10M 0.10M 0.10M 0.10M 0.10M
Retained earnings -159.80000M -212.40000M 734.00M 734.00M 957.80M
Other liab - - - 90.40M 156.80M
Good will - - 218.20M 218.20M 224.90M
Other assets 3.60M 7.20M - 191.30M 57.30M
Cash 205.40M 99.50M 642.60M 642.60M 576.10M
Cash and equivalents 205.40M 99.50M - 642.60M 576.10M
Total current liabilities 132.20M 162.40M 1229.90M 1229.90M 373.80M
Current deferred revenue - - 26.40M - 140.40M
Net debt 366.70M 576.60M 763.20M 763.20M 264.90M
Short term debt 0.00000M 2.70M 957.30M 957.30M 31.60M
Short long term debt - - 413.70M 957.30M 31.60M
Short long term debt total 572.10M 676.10M 1405.80M 1405.80M 841.00M
Other stockholder equity 689.80M 700.30M 645.80M 645.80M 677.20M
Property plant equipment 216.00M 282.30M - 817.60M 800.10M
Total current assets 662.50M 598.70M 1210.70M 1210.70M 1272.10M
Long term investments - - - - -
Net tangible assets - - - 1383.00M 1619.00M
Short term investments - - 8.50M - -
Net receivables 84.20M 154.50M 158.40M 158.40M 274.70M
Long term debt 572.10M 663.70M 446.50M 448.50M 809.40M
Inventory 343.40M 311.70M 351.80M 351.80M 350.80M
Accounts payable 55.60M 60.90M 103.50M 103.50M 128.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -7.50000M -5.20000M 3.10M 3.10M -16.10000M
Additional paid in capital - - - - -
Common stock total equity - - - 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 734.00M 957.80M
Treasury stock - - - -227.70000M -152.20000M
Accumulated amortization - - - - -
Non currrent assets other 14.20M 18.90M 191.30M 191.30M 57.30M
Deferred long term asset charges - - - - -
Non current assets total 656.10M 791.00M 1955.90M 1955.90M 1686.90M
Capital lease obligations - - - - -
Long term debt total 572.10M 663.70M - 448.50M 809.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 125.20M 178.30M -381.30000M -225.00000M
Change to liabilities - - - -52.00000M -7.70000M
Total cashflows from investing activities 69.40M 125.20M - -381.30000M -225.00000M
Net borrowings -108.70000M -198.40000M - 564.20M -35.90000M
Total cash from financing activities -136.60000M -190.00000M 481.20M 481.20M -141.00000M
Change to operating activities - - - -86.50000M -29.90000M
Net income 52.60M -190.60000M -223.80000M -223.80000M 230.90M
Change in cash 103.50M -6.10000M 66.30M 66.30M -45.20000M
Begin period cash flow 105.60M 111.70M 576.30M 576.30M 621.50M
End period cash flow 209.10M 105.60M 642.60M 642.60M 576.30M
Total cash from operating activities 170.60M 58.70M -34.10000M -34.10000M 321.10M
Issuance of capital stock 0.00000M 9.30M 8.40M 0.00000M 0.00000M
Depreciation 95.80M 108.80M 143.30M 143.30M 123.80M
Other cashflows from investing activities 83.20M 148.10M - -21.80000M -21.80000M
Dividends paid - - 5.00M - 15.90M
Change to inventory -30.30000M -24.50000M -51.90000M -51.90000M -44.00000M
Change to account receivables 25.50M -24.40000M 114.70M 114.70M -48.20000M
Sale purchase of stock -24.90000M 24.20M -82.10000M -82.10000M -106.00000M
Other cashflows from financing activities -1.40000M -0.90000M 597.10M 597.10M -35.00000M
Change to netincome - - - 41.80M 118.70M
Capital expenditures 13.80M 22.90M 115.80M 115.80M 225.00M
Change receivables - - - 114.70M -48.20000M
Cash flows other operating - - - -10.30000M -56.50000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 65.80M -44.90000M
Change in working capital -22.40000M 88.70M 0.50M 0.50M -94.70000M
Stock based compensation 16.20M 18.00M 45.10M 45.10M 42.40M
Other non cash items 32.40M 39.30M 19.80M 19.80M -28.20000M
Free cash flow 156.80M 35.80M -149.90000M -149.90000M 96.10M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EBS
Emergent Biosolutions Inc		 -0.37 4.38% 8.07 8.60 2.08 0.56 0.82 1.13 3.35
ZTS
Zoetis Inc		 -0.08 0.10% 79.44 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -1.13 3.48% 31.32 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -5.4 3.30% 158.31 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.13 0.32% 40.45 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Emergent Biosolutions Inc

300 Professional Drive, Gaithersburg, MD, United States, 20879

Key Executives

Name Title Year Born
Mr. Robert G. Kramer Sr. CEO, Pres & Exec. Director 1957
Mr. Richard S. Lindahl Exec. VP, CFO & Treasurer 1964
Mr. Adam R. Havey Exec. VP & COO 1971
Mr. Atul Saran Exec. VP & Chief Strategy and Devel. Officer 1973
Mr. Robert G. Burrows VP of Investor Relations NA
Ms. Jennifer L. Fox Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. NA
Ms. Coleen Glessner Exec. VP of Global Quality and Ethics & Compliance NA
Ms. Lynn Kieffer VP of Corp. Communications NA
Ms. Katherine Strei Exec. VP of HR & Chief HR Officer 1962
Mr. Richard S. Lindahl M.B.A. Executive VP, CFO & Treasurer 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.